Cerity Partners
NVO

Cerity Partners’s Novo Nordisk NVO Stock Holding History

Cerity Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$882K Hold
18,400
– – ﹤0.01% 2074
2026
Q1 		$676K Hold
18,400
– – ﹤0.01% 2100
2025
Q4 		$322K Buy
+18,400
New +$941K ﹤0.01% 2368

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cerity Partners's NVO Position: Q2 2026 in Review

Cerity Partners increased its Novo Nordisk (NVO) stake by 13% in Q2 2026, buying an estimated $2.57M and bringing the position to 534,219 shares worth $25.6M. The position accounts for 0.03% of the portfolio, ranked #409.

Cerity Partners first reported a position in NVO in Q4 2017 and has held it in 22 quarters since. The position peaked at $94.1M in Q3 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Cerity Partners held 534,219 shares of Novo Nordisk worth $25.6M as of Q2 2026.
  • Cerity Partners bought 59,736 Novo Nordisk shares in Q2 2026, an estimated $2.57M.
  • Novo Nordisk made up 0.03% of Cerity Partners's portfolio in Q2 2026, its #409 holding.
  • Cerity Partners first reported a position in Novo Nordisk in Q4 2017 and has held it in 22 quarters since.
  • Cerity Partners's Novo Nordisk position peaked at $94.1M in Q3 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.